Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
View Top Employees from Outlook Therapeutics, Inc.Website | http://www.outlooktherapeutics.com |
Ticker | NASDAQ:ONS |
Employees | 40 (34 on RocketReach) |
Founded | 2011 |
Address | 7 Clarke Dr, Cranbury, New Jersey 08512, US |
Phone | (609) 619-3990 |
Technologies |
JavaScript,
HTML,
PHP
+33 more
(view full list)
|
Industry | Biotechnology Research, Biopharma, Biotechnology, Health Care, Science and Engineering, Pharmaceutical, Therapeutics |
Looking for a particular Outlook Therapeutics, Inc. employee's phone or email?
Terry Dagnon is the Chief Operations Officer of Outlook Therapeutics, Inc..
34 people are employed at Outlook Therapeutics, Inc..
Outlook Therapeutics, Inc. is based in Cranbury, New Jersey.